$TJX

Nemerov Jackwyn sold $161K of TJX

Nemerov Jackwyn sold 957 shares of TJX COMPANIES INC /DE/ (TJX) at $168.60 ($0.16M total) on 2026-06-11.

Original reporting
SEC EDGAR · Nemerov Jackwyn
Published Jun 12, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 12, 2026, 8:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TJX
Neutral
high confidence
Mentioned
$TJX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TJXNeutralLow
01

Why it matters

Insider selling can marginally influence sentiment, but the disclosure contains no new operational, earnings, or regulatory information about TJX.

02

Market read

A director’s open-market sale is disclosed; traders may note sentiment but should not treat it as a fundamental catalyst.

03

What to watch

Director holdings after sale (802 shares) suggest continued ownership; without context on total compensation or prior sales, the signal is weak.

Relevance 4/10Novelty 2/10Timing: Filed 2026-06-12 (transaction dated 2026-06-11)

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for TJX.

Company-level read

Ticker impact

$TJXNeutralHigh confidence
Context

TJX director Nemerov Jackwyn filed an open-market sale of 957 shares at $168.5950 on 2026-06-11, leaving 802 shares.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is an insider sale (not a buy), small relative to company size, and explicitly states no 10b5-1 plan, but provides no new company-specific operating or regulatory catalyst.

Market effects

No clear read-through to retail/discount apparel sector fundamentals from a single director sale.

None.

None.

Counterpoint

The sale may be liquidity-driven (taxes/diversification) rather than a bearish view on TJX; absence of a 10b5-1 plan doesn’t automatically imply negative information.

Key entities

  • TJX COMPANIES INC /DE/

    Subject of the Form 4 insider transaction disclosure.

  • Nemerov Jackwyn

    Director who sold 957 shares of TJX in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TJXHighAI 8/10

TJX Raises Fiscal 2027 Outlook as Q2 Results Show Broad-Based Growth

TJX raised its fiscal 2027 profit and earnings outlook after Q2 results exceeded expectations. Adjusted earnings rose 11% to $1.22 per share, and net sales increased 5% to $15.18 billion. Management also increased its long-term store target. Marmaxx, the largest division, showed the weakest growth at 1%, while other divisions performed better.

$TJXMedAI 8/10

Should Investors Buy TJX as Growth Improves but Valuation Stays Rich?

TJX reported strong Q2 results with rising sales and raised its fiscal 2027 earnings guidance to $5.15-$5.20 per share. The company plans to expand its store count to 7,500 and accelerate growth. However, its valuation remains high, with a forward P/S ratio of 2.06, above industry and historical averages. TJX's cash flow and shareholder returns are robust, but execution and cost pressures remain risks.

$TJXHighAI 8/10

TJX Falls 17.4% in the Past Month as Strong Results Meet Key Risks

TJX Companies Inc. (TJX) shares fell 17.4% in the past month despite beating Q2 earnings estimates and raising its full-year outlook. Q2 sales rose 5% to $15.18B, but Marmaxx's 1% comparable sales growth missed expectations. Management cited merchandise mix issues. TJX faces cost pressures from wages, fuel, and currency fluctuations, with Q3 gross margin expected to decline. The stock's valuation remains high, trading at a premium to its sub-industry and historical median.

$TJXMed

Tjx stock hits 52-week low at 125.5 USD

TJX Companies' stock hit a 52-week low of $125.49, down 26% from its high. Despite a 1-year decline of 9.66% and YTD losses of 17%, InvestingPro suggests it may be undervalued. Q2 fiscal 2027 results beat estimates, with $15.2B revenue and $1.22 EPS. Analysts have mixed views, with Jefferies downgrading to Hold, Bernstein maintaining Outperform, and UBS raising its target to $198.